BACKGROUND: Coffee and tea are widely consumed globally and are rich sources of potential chemopreventive compounds. Epidemiologic data for coffee and tea intakes in relation to colorectal cancer remain unclear. Despite differences in gut physiology, few studies have conducted investigations by anatomic subsites. OBJECTIVE: We evaluated coffee and tea intakes (caffeinated and decaffeinated) in relation to colon (proximal and distal) and rectal cancers. DESIGN: The NIH-AARP Diet and Health Study included 489,706 men and women who completed a baseline (1995-1996) self-administered questionnaire of demographics, diet, and lifestyle. Over a median of 10.5 y of follow-up, we identified 2863 proximal colon, 1993 distal colon, and 1874 rectal cancers. Multivariable HRs and 95% CIs were estimated by using Cox regression. RESULTS: Approximately 16% of participants drank ≥4 cups coffee/d. Compared with nondrinkers, drinkers of 4-5 cups coffee/d (HR: 0.85; 95% CI: 0.75, 0.96) and ≥6 cups coffee/d (HR: 0.74; 95% CI: 0.61, 0.89; P-trend < 0.001) had a lower risk of colon cancer, particularly of proximal tumors (HR for ≥6 cups/d: 0.62; 95% CI: 0.49, 0.81; P-trend < 0.0001). Results were similar to those overall for drinkers of predominantly caffeinated coffee. Although individual HRs were not significant, there was a significant P-trend for both colon and rectal cancers for people who drank predominantly decaffeinated coffee. No associations were observed for tea. CONCLUSIONS: In this large US cohort, coffee was inversely associated with colon cancer, particularly proximal tumors. Additional investigations of coffee intake and its components in the prevention of colorectal cancer by subsites are warranted. The NIH-AARP Diet and Health Study was registered at clinicaltrials.gov as NCT00340015.
BACKGROUND: Coffee and tea are widely consumed globally and are rich sources of potential chemopreventive compounds. Epidemiologic data for coffee and tea intakes in relation to colorectal cancer remain unclear. Despite differences in gut physiology, few studies have conducted investigations by anatomic subsites. OBJECTIVE: We evaluated coffee and tea intakes (caffeinated and decaffeinated) in relation to colon (proximal and distal) and rectal cancers. DESIGN: The NIH-AARP Diet and Health Study included 489,706 men and women who completed a baseline (1995-1996) self-administered questionnaire of demographics, diet, and lifestyle. Over a median of 10.5 y of follow-up, we identified 2863 proximal colon, 1993 distal colon, and 1874 rectal cancers. Multivariable HRs and 95% CIs were estimated by using Cox regression. RESULTS: Approximately 16% of participants drank ≥4 cups coffee/d. Compared with nondrinkers, drinkers of 4-5 cups coffee/d (HR: 0.85; 95% CI: 0.75, 0.96) and ≥6 cups coffee/d (HR: 0.74; 95% CI: 0.61, 0.89; P-trend < 0.001) had a lower risk of colon cancer, particularly of proximal tumors (HR for ≥6 cups/d: 0.62; 95% CI: 0.49, 0.81; P-trend < 0.0001). Results were similar to those overall for drinkers of predominantly caffeinated coffee. Although individual HRs were not significant, there was a significant P-trend for both colon and rectal cancers for people who drank predominantly decaffeinated coffee. No associations were observed for tea. CONCLUSIONS: In this large US cohort, coffee was inversely associated with colon cancer, particularly proximal tumors. Additional investigations of coffee intake and its components in the prevention of colorectal cancer by subsites are warranted. The NIH-AARP Diet and Health Study was registered at clinicaltrials.gov as NCT00340015.
Authors: A Schatzkin; A F Subar; F E Thompson; L C Harlan; J Tangrea; A R Hollenbeck; P E Hurwitz; L Coyle; N Schussler; D S Michaud; L S Freedman; C C Brown; D Midthune; V Kipnis Journal: Am J Epidemiol Date: 2001-12-15 Impact factor: 4.897
Authors: Wolfgang W Huber; Candee H Teitel; Brian F Coles; Roberta S King; Frederick W Wiese; Keith R Kaderlik; Daniel A Casciano; Joseph G Shaddock; Gerard J Mulder; Kenneth F Ilett; Fred F Kadlubar Journal: Environ Mol Mutagen Date: 2004 Impact factor: 3.216
Authors: Erikka Loftfield; Neal D Freedman; Barry I Graubard; Kristin A Guertin; Amanda Black; Wen-Yi Huang; Fatma M Shebl; Susan T Mayne; Rashmi Sinha Journal: Am J Epidemiol Date: 2015-11-27 Impact factor: 4.897
Authors: Erikka Loftfield; Meredith S Shiels; Barry I Graubard; Hormuzd A Katki; Anil K Chaturvedi; Britton Trabert; Ligia A Pinto; Troy J Kemp; Fatma M Shebl; Susan T Mayne; Nicolas Wentzensen; Mark P Purdue; Allan Hildesheim; Rashmi Sinha; Neal D Freedman Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-05-21 Impact factor: 4.254
Authors: James J Goedert; Joshua N Sampson; Steven C Moore; Qian Xiao; Xiaoqin Xiong; Richard B Hayes; Jiyoung Ahn; Jianxin Shi; Rashmi Sinha Journal: Carcinogenesis Date: 2014-07-18 Impact factor: 4.944